These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 25246738)
1. Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy. Seo WI; Kang PM; Kang DI; Yoon JH; Kim W; Chung JI J Korean Med Sci; 2014 Sep; 29(9):1212-6. PubMed ID: 25246738 [TBL] [Abstract][Full Text] [Related]
2. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869 [TBL] [Abstract][Full Text] [Related]
3. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score. Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791 [TBL] [Abstract][Full Text] [Related]
5. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719 [TBL] [Abstract][Full Text] [Related]
6. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy. Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003 [TBL] [Abstract][Full Text] [Related]
7. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031 [TBL] [Abstract][Full Text] [Related]
8. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084 [No Abstract] [Full Text] [Related]
9. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Loeb S; Carvalhal GF; Kan D; Desai A; Catalona WJ Urol Oncol; 2012 Sep; 30(5):584-9. PubMed ID: 20822930 [TBL] [Abstract][Full Text] [Related]
10. Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy. Hernández Hernández C; Kim Lee D; Sanchez Pérez M; Escobar SH Clin Genitourin Cancer; 2019 Jun; 17(3):e645-e649. PubMed ID: 31097389 [TBL] [Abstract][Full Text] [Related]
11. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786 [TBL] [Abstract][Full Text] [Related]
12. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cooperberg MR; Hilton JF; Carroll PR Cancer; 2011 Nov; 117(22):5039-46. PubMed ID: 21647869 [TBL] [Abstract][Full Text] [Related]
13. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy. Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731 [TBL] [Abstract][Full Text] [Related]
14. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Yoshida T; Nakayama M; Takeda K; Arai Y; Kakimoto K; Nishimura K Urol Int; 2012; 89(1):45-51. PubMed ID: 22441013 [TBL] [Abstract][Full Text] [Related]
15. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. Cooperberg MR; Broering JM; Carroll PR J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351 [TBL] [Abstract][Full Text] [Related]
16. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer. Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896 [TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
18. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570 [TBL] [Abstract][Full Text] [Related]
19. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710 [TBL] [Abstract][Full Text] [Related]
20. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]